Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Status:
Active, not recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the role of addition of an anti-angiogenic agent
(Nintedanib/placebo) to conventional combination chemotherapy as concomitant and maintenance
treatment in primary advanced or with first relapse of endometrial cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Nordic Society for Gynaecologic Oncology Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Collaborators:
ARCAGY/ GINECO GROUP Belgian Gynaecological Oncology Group North Eastern German Society of Gynaecological Oncology North Eastern Germany Society of Gynaecologic Oncology